NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Dabigatran etexilate for the prevention of stroke in atrial fibrillation

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors Boehringer- Ingelheim (dabigatran) Patient/carer groups Action Heart Afiya Trust Age Concern England Anticoagulation UK (ACE) Arrhythmia Alliance Black Health Agency British Cardiac Patients Association British Ethnic Health Awareness Foundation (BEHAF) Cardiac Risk in the Young (CRY) Cardiomyopathy Association Chinese National Healthy Living Centre Confederation of Indian Organisations Counsel and Care Different Strokes Equalities National Council Heart Care Partnership (UK) HEART UK Help the Aged Muslim Council of Great Britain Muslim Health Network South Asian Health Foundation Specialised Healthcare Alliance	 General Age Concern Cymru Board of Community Health Councils in Wales British Cardiovascular Industry Association British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Public Health Service for Wales NHS Alliance NHS Confederation NHS Purchasing and Supply Agency NHS Quality Improvement Scotland Scottish Medicines Consortium Possible comparator manufacturers Actavis UK (aspirin, warfarin) Alliance Pharmaceuticals (aspirin) Aspar Pharmaceuticals (aspirin) Aspar Pharmaceuticals (aspirin) Bayer (aspirin) Bristol-Myers Squibb (aspirin) C P Pharmaceuticals (aspirin) Dexcel-Pharma (aspirin)
 Professional groups British Association for Nursing in Cardiac Care British Association for Service to the Elderly 	 Focus Pharmaceuticals (aspirin) Galpharm International (aspirin) Generics UK (aspirin, warfarin) Genus Pharmaceuticals (aspirin) Goldshield Pharmaceuticals (warfarin) IVAX Pharmaceuticals (aspirin,

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of dabigatran etexilate for the prevention of stroke in atrial fibrillation

Consultees Commentators (no right to submit or appeal) warfarin) British Association of Stroke Kent Pharmaceuticals (aspirin, warfarin) **Physicians** British Cardiovascular Intervention Napp Pharmaceuticals (aspirin) Society (BCIS) Pinewood Healthcare(aspirin) British Cardiovascular Society Reckitt Benckiser (aspirin) **British Geriatrics Society** Sandoz (aspirin, warfarin) **British Heart Foundation** Sterwin Medicines(aspirin) British Society for Heart Failure Sigma Pharmaceuticals (aspirin) Heart Rhythm UK Teva UK (aspirin, warfarin) National Heart Forum (UK) Thornton & Ross (aspirin) • Primary Care Cardiovascular Society Wockhardt UK (aspirin) Royal College of General Practitioners Winthrop Pharmaceuticals (warfarin) Royal College of Nursing Relevant research groups Royal College of Pathologists British Society for Cardiovascular Royal College of Physicians Cardiology Committee Research [BCS affiliated] Royal Society of Medicine – Cardiovascular Diseases Specialist Intellectual Disabilities Forum Library (CVDSL) Society for Cardiological Science & Central Cardiac Audit Database Cochrane Heart Group Technology United Kingdom Clinical Pharmacy Cochrane Peripheral Vascular Diseases Association Group Vascular Society Cochrane Stroke Group CORDA Others National Institute for Health Research Department of Health Policy Research Institute on Ageing and Richmond and Twickenham PCT **Ethnicity** Salford Teaching PCT Research Institute for the Care of Older Welsh Assembly Government United Kingdom Clinical Research Network Wellcome Trust - Cardiovascular Research Initiative **Evidence Review Group** Evidence Review Group tbc National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> National Collaborating Centre for **Chronic Conditions**

National Institute for Health and Clinical Excellence Provisional matrix for the appraisal of dabigatran etexilate for the prevention of stroke in atrial fibrillation

Appendix C

Consultees	Commentators (no right to submit or appeal)
	Associated Public Health Groups • tbc

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.